These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34876925)

  • 1. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis.
    Hellwig K; Verdun di Cantogno E; Sabidó M
    Ther Adv Neurol Disord; 2021; 14():17562864211051012. PubMed ID: 34876925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis.
    Bove R; Applebee A; Bawden K; Fine C; Shah A; Avila RL; Belviso N; Branco F; Fong K; Lewin JB; Liu J; England SM; Vignos M
    Mult Scler Relat Disord; 2024 Aug; 88():105738. PubMed ID: 38959591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
    Haben S; Ciplea AI; Tokic M; Timmesfeld N; Thiel S; Gold R; Langer-Gould AM; Hellwig K
    J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):151-157. PubMed ID: 37536925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience.
    Zanghì A; D'Amico E; Callari G; Chisari CG; Borriello G; Grimaldi LME; Patti F
    Front Neurol; 2020; 11():105. PubMed ID: 32158424
    [No Abstract]   [Full Text] [Related]  

  • 5. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP
    J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Yeh WZ; Widyastuti PA; Van der Walt A; Stankovich J; Havrdova E; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout BI; Lechner-Scott J; Sola P; Skibina OG; Barnett M; Onofrj M; Sá MJ; McCombe PA; Grammond P; Ampapa R; Grand'Maison F; Bergamaschi R; Spitaleri DLA; Van Pesch V; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Gresle M; Uher T; Maimone D; Turkoglu R; Hupperts RM; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell RA; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis VG;
    Neurology; 2021 Jun; 96(24):e2989-e3002. PubMed ID: 33879599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.
    Lescot L; Lefort M; Leguy S; Le Page E; Vukusic S; Edan G; Kerbrat A; Lebrun-Frenay C; De Sèze J; Laplaud DA; Wiertlewski S; Leray E; Michel L
    Mult Scler Relat Disord; 2022 Dec; 68():104122. PubMed ID: 36037756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses: A Retrospective Analysis.
    Vieira MC; Li Y; Meng X; Zhou H; Piao OW; Kutz C; Conway D
    Int J MS Care; 2021; 23(2):73-78. PubMed ID: 33880083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.
    Villaverde-González R
    Degener Neurol Neuromuscul Dis; 2022; 12():1-21. PubMed ID: 35023987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
    Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
    Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.